D-0877-2023 Class III Terminated

Recalled by Aurolife Pharma, LLC — Dayton, NJ

FDA drug recall D-0877-2023 was initiated by Aurolife Pharma, LLC on May 18, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications The recall status is terminated (terminated August 28, 2024).

Recall Details

Product Type
Drugs
Report Date
June 28, 2023
Initiation Date
May 18, 2023
Termination Date
August 28, 2024
Voluntary/Mandated
Product Quantity

Product Description

Glycopyrrolate Tablets, USP, 1 mg, 100-count bottles, Rx Only, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ 08520, NDC 13107-014-01

Reason for Recall

Failed Impurities/Degradation Specifications

Distribution Pattern

Nationwide within the United States

Code Information

Lot #: 01421038A1, Exp. Date 05/2023